Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

Globe Newswire - Wed Jun 8, 2022

- 73 Ambulatory DMD Patients Enrolled -
- Topline Data Anticipated 2H:2023 -

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy (DMD).

Read more at globenewswire.com

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).